Sanofi Settlement With Lilly Paves The Way For Biosimilar Lantus
Eli Lilly’s copycat version of Sanofi’s blockbuster insulin Lantus could reach the market in the U.S. in December 2016 following a settlement agreement with Sanofi.
Eli Lilly’s copycat version of Sanofi’s blockbuster insulin Lantus could reach the market in the U.S. in December 2016 following a settlement agreement with Sanofi.